Trial Profile
A Phase 3, Single Arm, 24-Week, Multicenter Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant HIV-1
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Oct 2022
Price :
$35
*
At a glance
- Drugs Ibalizumab (Primary)
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Sponsors TaiMed Biologics
- 18 Oct 2022 Results from TMB-301 and TMB-311, characterizing complexity of OBR and assessing its impact on durability of response to IBA, presented in 24th Intl AIDS Conference
- 12 May 2022 A systematic literature review was conducted to identify trials with designs and populations comparable to BRIGHTE, results published in the Clinical Therapeutics
- 21 Jul 2021 Results of subgroup analysis evaluating impact of the post-attachment inhibitor ibalizumab (IBA) on weight as well as potential risk factors in treatment-experienced patients presented at the 11th International AIDS Society Conference on HIV Science